ESIH:XETRA:XETRA-iShares MSCI Europe Health Care Sector UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 7.3

Change

-0.06 (-0.86)%

Market Cap

USD 0.60B

Volume

0.07M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-23 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.43 (+0.84%)

USD 484.40B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.15 (+0.88%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.26 (+0.97%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.20 (+0.71%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.23 (+0.94%)

USD 157.79B
8R80:XETRA Amundi Index Solutions - Amund..

+0.56 (+0.39%)

USD 98.29B
JARI:XETRA Amundi Index Solutions - Amund..

+0.23 (+0.49%)

USD 98.25B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.45 (+0.88%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+3.72 (+0.69%)

USD 80.38B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

+0.18 (+0.79%)

USD 79.79B

ETFs Containing ESIH:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 15.21% 79% B- 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.21% 78% C+ 76% C+
Trailing 12 Months  
Capital Gain 14.21% 53% F 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.21% 52% F 55% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 4.72% 49% F 49% F
Dividend Return 4.72% 49% F 47% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 6.54% 76% C+ 81% B-
Risk Adjusted Return 72.17% 73% C 76% C+
Market Capitalization 0.60B 69% C- 60% D-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.